Sol-Gel Technologies Ltd.
Sol-Gel is a dermatology company that develops topical treatments for skin conditions. Its products include FDA-approved Twyneo, a once-daily cream combining encapsulated benzoyl peroxide and tretinoin for acne vulgaris, and Epsolay, a once-daily cream containing encapsulated benzoyl peroxide for inflammatory lesions of rosacea. Sol-Gel sold its U.S. rights to both products to Mayne in April 2025 and licenses or commercializes product rights through partners in other markets. Sol-Gel also develops product candidates for severe and rare skin conditions. SGT-610 is a topical patidegib gel in a Phase 3 trial for preventing new basal cell carcinomas in people with Gorlin syndrome. SGT-210 is a topical erlotinib platform being considered for new indications. The company makes money through product rights agreements, including upfront and milestone payments and royalties on sales. Its principal executive offices are in Ness Ziona, Israel.
No enriched coverage for $SLGL in the last 7 days.
No SEC Form 4 filings for $SLGL in the last 30 days.
See all $SLGL insider activity →HC Wainwright & Co. maintained a Buy rating on Sol-Gel Technologies (SLGL) with a $110 price target, suggesting a 71.2% upside. The firm cited a favorable commercial outlook for SGT-610 and upcoming pivotal trial results as key catalysts.
Sol-Gel Technologies (SLGL) anticipates a 2028 launch for SGT-610, targeting Gorlin Syndrome. Management believes the drug could show a 40% treatment difference in reducing BCCs. The company estimates a $860M U.S. market opportunity with 4,000 treated patients at peak. Sol-Gel plans to commercialize the drug independently in the U.S. and seek partners abroad.
H.C. Wainwright reiterated a Buy rating and $110 price target for Sol-Gel Technologies (SLGL), citing the upcoming Phase 3 trial data for SGT-610, its lead drug candidate. The stock has risen 84% in the past year to $78.95, with a market cap of $258 million. The trial aims to prevent new basal cell carcinoma lesions in Gorlin syndrome patients, with potential FDA submission in 2027 and approval in late 2027. InvestingPro analysis suggests the stock may be overvalued.
Recent SLGL coverage spans insider activity, financial news and earnings.
HC Wainwright & Co. maintained a Buy rating on Sol-Gel Technologies (SLGL) with a $110 price target, suggesting a 71.2% upside. The firm cited a favorable commercial outlook for SGT-610 and upcoming pivotal trial results as key catalysts.
The trial data could materially affect SLGL valuation; positive results may trigger a sharp price rally, while negative or delayed data could depress the stock.
Analyst upgrade may lift the stock ahead of trial readout.
Small insider purchase likely reflects confidence but unlikely to move the stock materially.
The insider purchase signals confidence from a 10% owner, modestly bullish for SLGL.
AlphAI scores every news story that mentions SLGL with an AI model for sentiment and relevance, and aggregates insider trades from Sol-Gel Technologies Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. maintained a Buy rating on Sol-Gel Technologies (SLGL) with a $110 price target, suggesting a 71.2% upside. The firm cited a favorable commercial outlook for SGT-610 and upcoming pivotal trial results as key catalysts.
2 min readSol-Gel Technologies (SLGL) anticipates a 2028 launch for SGT-610, targeting Gorlin Syndrome. Management believes the drug could show a 40% treatment difference in reducing BCCs. The company estimates a $860M U.S. market opportunity with 4,000 treated patients at peak. Sol-Gel plans to commercialize the drug independently in the U.S. and seek partners abroad.
1 min readH.C. Wainwright reiterated a Buy rating and $110 price target for Sol-Gel Technologies (SLGL), citing the upcoming Phase 3 trial data for SGT-610, its lead drug candidate. The stock has risen 84% in the past year to $78.95, with a market cap of $258 million. The trial aims to prevent new basal cell carcinoma lesions in Gorlin syndrome patients, with potential FDA submission in 2027 and approval in late 2027. InvestingPro analysis suggests the stock may be overvalued.
1 min readOpaleye Management Inc. purchased 3,124 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $66.39 ($65.94–$66.80, $0.21M total) across 2 trades over 2026-09-10 to 2026-09-11.
1 min readOpaleye Management Inc. purchased 9,976 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $68.88 ($68.70–$69.52, $0.69M total) across 5 trades over 2026-09-04 to 2026-09-09.
1 min readOpaleye Management Inc. purchased 1,683 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $69.21 ($68.95–$69.52, $0.12M total) across 2 trades over 2026-09-01 to 2026-09-02.
1 min readOpaleye Management Inc. purchased 40,330 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at an average of $69.19 ($68.24–$71.40, $2.79M total) across 5 trades over 2026-08-28 to 2026-08-31.
1 min readSol-Gel Technologies Ltd. (SLGL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 • So
2 min readOpaleye Management Inc. purchased 951 indirectly-held shares of Sol-Gel Technologies Ltd. (SLGL) at $71.50 on 2026-08-12.
2 min readBiotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.
6 min read
